CHICAGO, May 2, 2013 (GLOBE NEWSWIRE) -- Durata Therapeutics (Nasdaq:DRTX) has scheduled its quarterly conference call for Thursday, May 9 at 8:30 a.m. Eastern Time to discuss first quarter 2013 financial results. The conference call will be available via phone and webcast. To access the call, please dial 866-632-4021 for participants in the U.S. or Canada and 404-991-3968 for international callers (reference Conference ID 63029636). A replay of the call may be accessed through May 23, 2013 by dialing 800-585-8367 for callers in the U.S. and Canada and 404-537-3406 for international callers (reference Conference ID 63029636). The conference call will also be webcast live on the Investor Relations section of the Company's website at www.duratatherapeutics.com . About Durata Therapeutics Durata Therapeutics is a pharmaceutical company focused on the development and commercialization of novel therapeutics for patients with infectious diseases and acute illnesses. Durata has completed its DISCOVER 1 and DISCOVER 2 global Phase 3 clinical trials with its lead product candidate, dalbavancin, for the treatment of patients with acute bacterial skin and skin structure infections, or ABSSSI. Forward-looking statements Any statements in this press release about Durata's future expectations, plans and prospects constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, as amended. Actual results may differ materially from those indicated by such forward-looking statements. Durata anticipates that subsequent events and developments will cause its views to change. However, while Durata may elect to update these forward-looking statements at some point in the future, Durata specifically disclaims any obligation to do so.
CONTACT: Investor Relations and Public Affairs Contact Allison Wey - Durata Therapeutics Vice President, Investor Relations and Public Affairs (312)219-7017 - firstname.lastname@example.org